The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... That’s better than the €1.56 billion average of ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Intel Corporation, one of the world’s largest semiconductor designers and ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...